Celgene

Celgene is lurking in the background.

1. They purchased 45m shares in MSB for $3.82 in April 2015 for a 6 month first right of refusal to certain disease fields.

2. They extended the the first right of refusal for a further 6 months on 16 October 2015 with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection. This would have expired in April 2016.

In 2015 Celgene was busy and acquired Receptos for 7.2B

Celgene differentiates itself when it comes to deal-making. Celgene puts together multiple different deal structures -- collaborative partnerships, follow-on licensing deals, equity only acquisitions, you name it -- based on what the smaller target company needs. By allowing the latter to retain some of its own products, and not capping the financial upside, the little guy keeps pulling for all its worth.

They may re-enter the scene and snap up a bargain and a do a deal to cherry pick Tier 1 products and/or any emerging new products.

KEEP WATCH